- Home
- CLDX vs ABG Comparison
CLDX vs ABG Comparison
Compare CLDX & ABG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDX | ABG |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 1995 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CLDX | ABG |
|---|---|---|
| Price | $28.86 | $195.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | $64.00 | ★ $225.18 |
| AVG Volume (30 Days) | ★ 899.2K | 325.4K |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.88 |
| EPS | N/A | ★ 22.10 |
| Revenue | $12,743,000.00 | ★ $17,999,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.84 | $3.49 |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | ★ 87.78 | 4.71 |
| 52 Week Low | $22.33 | $160.30 |
| 52 Week High | $45.14 | $258.75 |
Technical Indicators
Market Signals| Indicator | CLDX | ABG |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 52.07 |
| Support Level | $28.26 | $183.28 |
| Resistance Level | $31.83 | $203.19 |
| Average True Range (ATR) | 1.44 | 9.25 |
| MACD | 0.15 | 0.53 |
| Stochastic Oscillator | 26.35 | 53.65 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About ABG Asbury Automotive Group Inc
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 158 new-vehicle stores and 37 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 14 states (mostly in Rocky Mountain states, Texas, the Northeast, and Southeast). Asbury store brands include Herb Chambers in the Northeast, McDavid and Park Place in Texas, Koons in the Washington, D.C., area, and the Larry H. Miller brand in the Western US. Asbury generated about $18 billion of revenue in 2025 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.